Target Price | $33.66 |
Price | $20.85 |
Potential |
61.44%
register free of charge
|
Number of Estimates | 13 |
13 Analysts have issued a price target Centessa Pharmaceuticals plc - ADR 2026 .
The average Centessa Pharmaceuticals plc - ADR target price is $33.66.
This is
61.44%
register free of charge
$42.00
101.44%
register free of charge
$27.27
30.79%
register free of charge
|
|
A rating was issued by 18 analysts: 17 Analysts recommend Centessa Pharmaceuticals plc - ADR to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Centessa Pharmaceuticals plc - ADR stock has an average upside potential 2026 of
61.44%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 0.00 | 15.30 |
100.00% |
14 Analysts have issued a sales forecast Centessa Pharmaceuticals plc - ADR 2025 . The average Centessa Pharmaceuticals plc - ADR sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Centessa Pharmaceuticals plc - ADR EBITDA forecast 2025. The average Centessa Pharmaceuticals plc - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Centessa Pharmaceuticals plc - ADR Analysts have issued a net profit forecast 2025. The average Centessa Pharmaceuticals plc - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.06 | -1.41 |
31.21% | 31.55% | |
P/E | negative | |
EV/Sales | 148.58 |
15 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast for earnings per share. The average Centessa Pharmaceuticals plc - ADR EPS is
This results in the following potential growth metrics and future valuations:
Centessa Pharmaceuticals plc - ADR...
Analyst | Rating | Action | Date |
---|---|---|---|
Wells Fargo |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Jul 30 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Jul 21 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 28 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
Analyst Rating | Date |
---|---|
Locked
Wells Fargo:
Locked
➜
Locked
|
Sep 03 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 12 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Jul 30 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Jul 21 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 28 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.